For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Entera Bio Ltd. (ENTX) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Entera Bio Ltd. is a member of the Medical sector. This group includes 1051 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges th ...

Entera Bio (ENTX) makes oral peptide therapies, validating its disruptive N-Tab oral peptide proprietary technology platform.Its leading pipeline candidate is EB613, an oral, osteoanabolic (bone building) once-daily tablet for treating osteoporosis, a bone disease that develops when bone mass decreases, leading to an increase in the risk of fractures. A phase IIb study of the EB613 tablets met the primary and secondary endpoints.Entera Bio plans to begin a phase III registrational study on EB613 once the FD ...

JERUSALEM, April 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides, announced today that data from the Phase 2 Trial of its lead clinical compound, EB613 (Oral PTH(1-34) Tablets) for the Treatment of Post-Menopausal Women with Low BMD or Osteoporosis compared to placebo were published in the Journal of Bone and Mineral Research (JBMR). Miranda Toledano, CEO of Entera, commented, "We are excited to share that data ...

合作研究项目 - Entera Bio Ltd.与OPKO Health, Inc.宣布合作研究开发口服肽类药物[1] - 项目旨在为患有短肠综合征和其他涉及黏膜炎症和营养吸收障碍的患者开发GLP-2肽片剂替代品[2] 药代动力学研究结果 - 首次验证性药代动力学研究在啮齿动物中取得成功，显示口服GLP-2片剂具有显著的系统暴露[3] - 口服GLP-2片剂的血浆浓度约为teduglutide的治疗性血浆浓度的10倍，表明口服片剂形式的GLP-2类似物在大鼠体内的半衰期约为teduglutide的6倍[4]

公司业绩 - Entera Bio Ltd.（NASDAQ:ENTX）报告了2023年第四季度和全年截至12月31日的财务业绩和关键业务更新[1] - 公司在2023年度的财务报表显示，营收为0，成本为101千美元，毛利润为33千美元[24] - 研发支出为4,510千美元，管理和行政支出为4,430千美元，总运营支出为8,891千美元[24] - 公司在2023年度录得净亏损为8,889千美元，基本和摊薄每股亏损分别为0.31和0.45美元[24] 产品发展 - 2023年是Entera的转折点，公司展示了其颠覆性的N-Tab™口服肽技术平台的持续验证，并公布了计划，到2025年底将五个潜在的首创口服肽项目（第一阶段至第三阶段）推进到临床阶段[2] - EB613是首个口服PTH(1-34)每日骨代谢促进片剂，用于骨质疏松症，具有独特的药代动力学特征，与需要每日皮下注射的Forteo® PTH(1-34) 20 µg相比，EB613表现出更高的Cmax和更短的系统暴露时间[3] - EB613的“脉冲”作用似乎同时刺激双重骨形成和轻微的抗吸收作用，预计在2024年将有关于SABRE和BMD资格认定过程的更新[4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ . Commission file number 001-38556 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 00-0000000 (State or Other Jurisdiction of (I ...

Exhibit 99.1 Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates JERUSALEM – March 8, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023. “2023 was an inflection point for Entera, with consistent validation of our disruptive N-Tab™ oral peptide technology platform and the u ...

JERUSALEM, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, announced that it will participate and be available for investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference being held February 13 – 14, 2024 in a virtual format. The presentation at 8am Wednesday, February 14th will feature a business overview and update by Miranda Toledano, the Company's C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38556 ENTERA BIO LTD. (Exact name of Registrant as specified in its charter) Israel Not applicable (State or other jurisdiction of (I. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38556 ENTERA BIO LTD. (Exact name of Registrant as specified in its charter) Israel Not applicable (State or other jurisdiction of (I.R.S. ...